Showing 1951-1960 of 2192 results for "".
- Neurotrophic Factor-Secreting Stem Cell Treatment Improves Function in Progressive Multiple Sclerosishttps://practicalneurology.com/news/neurotrophic-factor-secreting-stem-cell-treatment-improves-function-in-progressive-multiple-sclerosis/2470024/As published in Multiple Sclerosis, off-the-shelf growth factor-secreting stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treatment of people with progressive multiple sclerosis (MS) im
- Ecopipam Reduced Tics in Children and Adolescents With Tourette Syndromehttps://practicalneurology.com/news/ecopipam-reduced-tics-in-children-and-adolescents-with-tourette-syndrome/2470022/A recent study demonstrated efficacy and safety of ecopipam for treatment of Tourette syndrome (TS) in children and adolescents, ages 6 to 17 years. Both motor and phonic tics were reduced with ecopipam (n=74) compared with placebo (n=75). A statistically significant least
- Phase 3 Trial of Dextromethorphan-Bupropion for Agitation in Alzheimer Diseasehttps://practicalneurology.com/news/phase-3-trial-of-dextromethorphan-bupropion-for-agitation-in-alzheimer-disease/2470017/The first participant has been enrolled in the Addressing Dementia via Agitation-Centered Evaluation-2 (ADVANCE-2) trial (NCT03226522) of dextromethorphan-bupropion (AXS-05; Axsome Therapeutics, New York, NY), an investigational treatm
- New Intracranial Catheter System Provided Effective Clot Removal to Treat Middle Cerebral Artery Occlusions Causing Ischemic Strokehttps://practicalneurology.com/news/new-intracranial-catheter-system-provided-effective-clot-removal-to-treat-middle-cerebral-artery-occlusions-causing-ischemic-stroke/2470009/An intracranial catheter systtem (Zoom Stroke Solution; Imperative Care, Campbell, CA) for middle cerebral artery (MCA) M2 occlusions provided fast clot removal and reperfusion. In a single-center study, the majority of participants (92.7%) achieved Thrombolysis in Cerebral Infarction (TICI) 2b/3
- Physcial Exercise May Stall Cognitive Decline in Mild Cognitive Impairmenthttps://practicalneurology.com/news/physcial-exercise-may-stall-cognitive-decline-in-mild-cognitive-dementia/2469986/In the phase 3 EXERT trial (NCT02814526), 296 individuals, age 65 to 89, with amnestic mild cognitive impairment (MCI) who participated in supervised exercise programs maintained baseline cognitive abilities. Cognition was measure
- Visual Impairment in Hispanic/Latinx People May Be Associated With Worse Measures of Cognitionhttps://practicalneurology.com/news/visual-impairment-in-hispaniclatinx-people-may-be-associated-with-worse-measures-of-cognition/2469980/In a study conducted at the University of Miami Miller School of Medicine, Hispanic/Latinx people with self-reported vision problems had worse verbal fluency, memory, and processing speed/executive function). This correlation was found both at baseline and after 7 years of follow-up, with visual
- FDA Grants Priority Review of Tofersen for SOD-1 Amyotrophic Lateral Sclerosishttps://practicalneurology.com/news/fda-grants-priority-review-of-tofersen-for-for-sod-1-amyotrophic-lateral-sclerosis/2469973/The Food and Drug Administration (FDA) has agreed to priorty review of a New Drug Application (NDA) for tofersen (Biogen, Cambridge, MA) for treatment of superoxide dismutase-1 (SOD1) amyotrophic lateral sclerosis (ALS). According to the filed data for the NDA, tofersen slowed decline across meas
- Immuno-Infrared Sensor is Able to Identify Symptom-Free Alzheimer Diseasehttps://practicalneurology.com/news/immuno-infrared-sensor-is-able-to-identify-symptom-free-alzheimer-disease/2469972/Alzheimer disease (AD) is thought to begin 15 to 20 years before clinical symptoms are seen, making early identification of presymptomatic disease a priority. As published in the journal Alzheimer’s & Dementia, new results compared sensitivity of an immune-infrared sensor with the compl
- Phase 3 Trial for Buntanetap for Parkinson Disease Initiatedhttps://practicalneurology.com/news/phase-3-trial-for-buntanetap-for-parkinson-disease-initiated/2469966/A phase 3 trial (NCT05357989) of buntanetap (Annovis Bio, Berwyn, PA) for Parkinson disease (PD) has been okayed by the Food and Drug Administration (FDA). People with early PD (Hoehn & Yahr [
- Response to COVID-19 Vaccines Confirmed in People With Relapsing Multiple Sclerosis Treated With Ozanimodhttps://practicalneurology.com/news/response-to-covid-19-vaccines-confirmed-in-people-with-relapsing-multiple-sclerosis-treated-with-ozanimod/2469955/In the open-label extension of the DAYBREAK (NCT02576717) trial, participants with relapsing multiple sclerosis (RMS) being treated with ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) deve